NovoCure

Company Overview

Snapshot

Founded in April 1999 by Prof. Yoram Palti, NovoCure is a public oncology company with over 1,000 employees. The company has raised $742 million across five funding rounds and went public on NASDAQ in October 2015. In May 2024, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing.

Business overview

NovoCure is a commercial-stage oncology company focused on developing and commercializing its proprietary Tumor Treating Fields (TTFields) therapy for solid tumor cancers. This novel, non-invasive technology uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. The therapy is delivered via insulated transducer arrays placed on the skin, connected to a portable electric field generator. NovoCure's products, including Optune Lua and Optune Gio, are used in markets such as the United States, Japan, and Germany, serving patients and healthcare providers in the Health Tech & Life Sciences sector.

Strategic signal

NovoCure is poised for significant clinical validation and market expansion, with upcoming presentations of real-world data at ESMO 2024 demonstrating improved survival outcomes for glioblastoma patients using TTFields therapy. Additionally, the company is set to present final results from the pivotal Phase 3 METIS trial for brain metastases from non-small cell lung cancer at the 2025 ASTRO Annual Meeting. These events signal a strong commitment to advancing its core technology and expanding its therapeutic applications, which could significantly impact its market position and investor confidence.

Company Intelligence Q&A

What is NovoCure's primary therapeutic technology?

NovoCure develops Tumor Treating Fields (TTFields) therapy, a proprietary technology that uses low-intensity, intermediate-frequency alternating electric fields to disrupt mitosis and cytokinesis in solid tumor cancers.

When did NovoCure go public?

NovoCure went public on NASDAQ in October 2015.

What was a significant recent financial event for NovoCure?

In May 2024, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing.

What recent leadership change occurred at NovoCure?

In September 2024, NovoCure announced that CEO Asaf Danziger would retire, with CFO Ashley Cordova named as his successor.

What recent regulatory approval did NovoCure receive in Japan?

In September 2025, NovoCure obtained approval for its Optune Lua device in Japan for the treatment of unresectable advanced/recurrent non-small cell lung cancer (NSCLC).